Denali Historical Income Statement
| DNLI Stock | USD 21.93 0.26 1.20% |
Historical analysis of Denali Therapeutics income statement accounts such as Selling General Administrative of 124.8 M or Total Revenue of 399.1 M can show how well Denali Therapeutics performed in making a profits. Evaluating Denali Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Denali Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Denali Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Denali Therapeutics is a good buy for the upcoming year.
Denali |
About Denali Income Statement Analysis
Denali Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Denali Therapeutics shareholders. The income statement also shows Denali investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Denali Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Denali Therapeutics. It is also known as Denali Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Denali Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Denali Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.As of now, Denali Therapeutics' Gross Profit is increasing as compared to previous years. The Denali Therapeutics' current Other Operating Expenses is estimated to increase to about 636.6 M, while Interest Expense is projected to decrease to under 8.6 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Income | 14.8M | 51.5M | 59.2M | 62.2M | Net Interest Income | 14.8M | 45.0M | 51.8M | 54.4M |
Denali Therapeutics income statement Correlations
Click cells to compare fundamentals
Denali Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Denali Therapeutics income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 8.5M | 8.6M | 7.0M | 16.7M | 19.2M | 20.2M | |
| Interest Expense | 15.2M | 17.8M | 13.2M | 14.8M | 17.0M | 8.6M | |
| Selling General Administrative | 60.3M | 79.1M | 90.5M | 103.4M | 118.9M | 124.8M | |
| Total Revenue | 335.7M | 48.7M | 108.5M | 330.5M | 380.1M | 399.1M | |
| Gross Profit | 335.7M | 48.7M | 101.4M | 313.8M | 360.9M | 378.9M | |
| Other Operating Expenses | 272.9M | 344.4M | 449.2M | 527.2M | 606.3M | 636.6M | |
| Operating Income | 62.7M | (295.8M) | (340.7M) | (196.7M) | (177.0M) | (185.9M) | |
| Net Income From Continuing Ops | 72.8M | (290.6M) | (326.0M) | (124.4M) | (112.0M) | (117.6M) | |
| Ebit | 62.7M | (295.8M) | (337.4M) | (196.7M) | (177.0M) | (185.9M) | |
| Research Development | 212.6M | 265.4M | 358.7M | 423.9M | 487.5M | 511.8M | |
| Ebitda | 71.2M | (287.2M) | (330.4M) | (180.0M) | (162.0M) | (170.1M) | |
| Cost Of Revenue | 212.6M | 5.6M | 7.0M | 16.7M | 15.1M | 14.3M | |
| Total Operating Expenses | 272.9M | 344.4M | 449.2M | 527.2M | 606.3M | 636.6M | |
| Income Before Tax | 72.0M | (291.2M) | (326.0M) | (145.2M) | (130.7M) | (137.2M) | |
| Total Other Income Expense Net | 9.2M | 4.6M | 14.8M | 51.5M | 59.2M | 62.2M | |
| Net Income Applicable To Common Shares | (197.6M) | 71.1M | (290.6M) | (326.0M) | (293.4M) | (278.7M) | |
| Net Income | 71.1M | (290.6M) | (326.0M) | (145.2M) | (130.7M) | (137.2M) | |
| Income Tax Expense | 823K | (575K) | 21K | 30K | 27K | 25.7K | |
| Net Interest Income | 9.2M | 4.6M | 14.8M | 45.0M | 51.8M | 54.4M | |
| Interest Income | 9.2M | 4.6M | 14.8M | 51.5M | 59.2M | 62.2M | |
| Reconciled Depreciation | 8.5M | 8.6M | 10.4M | 18.6M | 21.4M | 22.5M | |
| Tax Provision | 823K | (575K) | 21K | (6K) | (5.4K) | (5.7K) |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.